PDE4A and schizophrenia: In particular, rolipram, a PDE type-4 (PDE4) inhibitor, has been shown to enhance cAMP signalling both in slices and in vivo (Bateup et al., 2008), as well as improving ED shift performance in rodent models of schizophrenia (Rodefer et al., 2012).